ZHB015 / Zonhon Biopharma Institute - LARVOL DELTA

Pre-clinical research of ZHB015, an anti-CD26/CD3 bispecific T-cell-engaging antibody (AACR 2025) - "Although FDA approved axitinib in combination with avelumab as the first-line treatment for PD-L1 positive advanced renal cell carcinoma in 2019, the problems still exist such as individual differences and drug tolerance. ZHB015 simultaneously binds to tumor CD26 and T cell CD3, inducing T cell mediated antitumor effects. ZHB015 has an outstanding anti-tumor activity in vitro and in vivo, which is superior to YS110 and the current first line treatment. Thus, ZHB015 is being further developed as a potential therapy for CD26 positive solid tumor."

IO biomarker • Preclinical • Genito-urinary Cancer • Kidney Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • DPP4 • PD-L1